• 1
    Connor EM, Sperling R, Gelber R, et al. Reduction of maternal–infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trial Group Protocol 076 Study Group. N Engl J Med 1994;331: 11731180.
  • 2
    Shaffer N, Chauchoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999;353: 773780.DOI: 10.1016/S0140-6736(98)10411-7
  • 3
    Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abijan, Cote d'Ivoire: a randomised trial. Lancet 1999;353: 781785.DOI: 10.1016/S0140-6736(98)10412-9
  • 4
    Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354: 759802.
  • 5
    Moodley D, for the SAINT Investigators team. The SAINT trial: nevirapine (NVP) versus zidovudine (ZDV) + lamivudine (3TC) in prevention of peripartum HIV transmission [Abstract LbOr2]. 13th International AIDS Conference, Durban, South Africa, 914 July 2000.
  • 6
    McIntyre J, Gray G. What can we do to reduce mother-to-child transmission of HIV. BMJ 2002;324(7331):218221.